A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064 ·Status: COMPLETED ·Phase: PHASE2

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

NCT02569476 ·Status: COMPLETED ·Phase: PHASE1

Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia

NCT06547866 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04458610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970 ·Status: COMPLETED ·Phase: PHASE2

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

NCT04282018 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

NCT03846427 ·Status: COMPLETED ·Phase: PHASE2

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

NCT03520920 ·Status: COMPLETED ·Phase: PHASE2

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

NCT05068440 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

NCT05200312 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

NCT06167785 ·Status: RECRUITING ·Phase: PHASE2

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

NCT04668365 ·Status: SUSPENDED ·Phase: PHASE2

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

NCT06116110 ·Status: RECRUITING

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

NCT00412321 ·Status: COMPLETED ·Phase: PHASE1

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019 ·Status: RECRUITING ·Phase: PHASE1

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04850495 ·Status: SUSPENDED ·Phase: PHASE1

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

NCT05887726 ·Status: UNKNOWN ·Phase: PHASE2

A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

NCT03299738 ·Status: UNKNOWN ·Phase: PHASE1

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862 ·Status: RECRUITING ·Phase: PHASE3

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

NCT00073749 ·Status: COMPLETED ·Phase: PHASE1

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

NCT03628677 ·Status: COMPLETED ·Phase: PHASE1

Randomised Trial in Waldenstrom's Macroglobulinaemia

NCT01592981 ·Status: COMPLETED ·Phase: PHASE2